Wenhui Zhao
-
- Breast Cancer Treatment Studies 3
- Oncology top 10%
- HER2/EGFR in Cancer Research 3
- Cancer Treatment and Pharmacology 2
- Cancer-related Molecular Pathways 2
-
- Estrogen and related hormone effects 3
-
- Advanced Breast Cancer Therapies 3
-
- Immune Cell Function and Interaction 2
-
- Inflammatory mediators and NSAID effects 2
- Cited by
- Cancer ResearchOncologyGenetics
- Journals
- Cancer Research (1 paper)The Lancet Oncology (1 paper)Biochemical and Biophysical Research Communications (1 paper)
- Partner nations
- ChinaUnited StatesCanada
In The Last Decade
Wenhui Zhao
19 papers receiving 440 citations
Peers
Comparison fields: 5 of 64
- Cancer Research 154
- Oncology 251
- Genetics 92
- Pulmonary and Respiratory Medicine 104
- Molecular Biology 154
Countries citing papers authored by Wenhui Zhao
This map shows the geographic impact of Wenhui Zhao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wenhui Zhao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wenhui Zhao more than expected).
Fields of papers citing papers by Wenhui Zhao
This network shows the impact of papers produced by Wenhui Zhao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wenhui Zhao. The network helps show where Wenhui Zhao may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Wenhui Zhao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 6 | |
| 2 | 2024 | 2 | |
| 3 | 2024 | 5 | |
| 4 | 2024 | 0 | |
| 5 | 2023 | 5 | |
| 6 | 2020 | 15 | |
| 7 | Apatinib-induced NF-κB inactivation sensitizes triple-negative breast cancer cells to doxorubicin. | 2020 | 14 |
| 8 | 2018 | 1 | |
| 9 | 2017 | 28 | |
| 10 | 2017 | 4 | |
| 11 | 2016 | 34 | |
| 12 | 2014 | 20 | |
| 13 | 2014 | 27 | |
| 14 | 2011 | 55 | |
| 15 | 2011 | 119 | |
| 16 | 2010 | 48 | |
| 17 | 2009 | 28 | |
| 18 | 2009 | 28 | |
| 19 | Risk factors for brain metastasis in patients of breast cancer | 2006 | 1 |
| 20 | The efficacy analysis of low-dose cyclophosphamide combined with ginsenoside Rg3 on advanced non-small cell lung cancer | 2006 | 6 |
About Wenhui Zhao
Wenhui Zhao is a scholar working on Oncology, Cancer Research and Pharmacology, having authored 20 papers that have together received 446 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (3 papers), Estrogen and related hormone effects (3 papers), Breast Cancer Treatment Studies (3 papers), HER2/EGFR in Cancer Research (3 papers), Immune Cell Function and Interaction (2 papers), Cancer Treatment and Pharmacology (2 papers), Inflammatory mediators and NSAID effects (2 papers) and Cancer-related Molecular Pathways (2 papers). The work is most often cited by research in Cancer Research (154 citations), Oncology (251 citations) and Genetics (92 citations). Wenhui Zhao has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Qingyuan Zhang, Dabei Tang, Qingyuan Zhang, Shanqi Xu, Xinmei Kang, Jingxuan Wang, Shu Zhao, Xu Huang, Ying Song and Wenjie Ma. Their work appears in journals such as Cancer Research, The Lancet Oncology and Biochemical and Biophysical Research Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.